Egypt Alopecia Therapeutics (Hair Loss) Market Report 2022 to 2030

Egypt Alopecia (Hair Loss) Therapeutics Market Analysis

$ 3999

The Egypt Alopecia (Hair Loss) Therapeutics Market was valued at US $23 Mn in 2022, and is predicted to grow at (CAGR) of 9% from 2023 to 2030, to US $46 Mn by 2030. The main drivers advancing this industry are primarily the significant rise in the prevalence of alopecia (hair loss), improved socioeconomic conditions, and others. The industry is primarily dominated by players such as Sun Pharmaceuticals, Johnson & Johnson, Cirrus, Cipla, Lexington, and Merck, among others.

ID: IN10EGPH430 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Riddhi Solanki

Buy Now

Egypt Alopecia Therapeutics Market Analysis: Executive Summary

The Egypt Alopecia Therapeutics Market is at around US $23 Mn in 2022 and is projected to reach US $46 Mn in 2030, exhibiting a CAGR of 9% during the forecast period.

Alopecia, a hereditary autoimmune condition also known as uneven hair loss, affects a large number of people. It can be localized or diffuse, transient or permanent, and impact people of all ages and genders. A condition caused by a variety of factors, including stress, diabetes, poor nutrition, smoking, and alcohol consumption, can affect the overall quality of life. Hair loss, thinning hair, and bare spots on the scalp are common symptoms. Treatment options include administering topical drugs such as minoxidil or corticosteroids directly to the scalp, as well as injections and oral treatments that have stronger immunosuppressive effects. Light treatment and hair transplants are also viable options. Notably, firms like Eli Lilly, with their JAK inhibitor Baricitinib, and Bayer, with Rogaine (Minoxidil), are actively leading advances in therapies.

The prevalence of alopecia areata in Egypt is estimated to be between 10% and 13%. The market is being propelled by factors such as the growing aging population and rise in alopecia, improving socioeconomic conditions, evolving treatment landscapes, and others. However, challenges such as lack of human resources, high costs, and regulatory challenges are a few factors that limit the market's potential.

Market Dynamics

Market Growth Drivers

Rising prevalence of Alopecia: It is estimated that the prevalence of Alopecia areata is over 10% up to 13% in Egypt, and it is known to affect mainly young adults in the first three decades of life. Emerging diagnostic modalities for alopecia contribute to increased market demand by facilitating better identification and diagnosis of the condition.

Improved socioeconomic conditions: Economic growth in Egypt results in increased disposable income, prompting individuals to show a greater willingness to invest in personal care and appearance-related treatments, including solutions for hair loss. Changing lifestyles in urban areas, influenced by Western trends, highlight the importance of hair care and aesthetics, leading to a heightened demand for effective alopecia treatments.

Evolving treatment landscape and innovation Emerging methods such as hair transplantation and platelet-rich plasma (PRP) therapy are becoming more widely accepted, providing less invasive alternatives for hair restoration. Progress in research and development is resulting in the introduction of novel medications and topical treatments, potentially offering enhanced effectiveness and more favorable side-effect profiles.

Market Restraints

Lack of specialists: Limited availability of specialized hair loss doctors, especially in regions outside major cities, can pose challenges for Egyptians in accessing accurate diagnosis and treatment options.

High cost of treatment: A considerable portion of the Egyptian population finds many alopecia treatments, such as JAK inhibitors, including medications, procedures, and hair restoration technologies, to be costly and beyond their financial reach, resulting in not seeing treatment or non-compliance that restricts market growth.

Regulatory hurdles: Securing approval for novel Alopecia treatments and technologies in Egypt can be a prolonged and complex procedure, constraining market accessibility and innovation. The existence of counterfeit or inferior hair loss products in the market has the potential to undermine trust and jeopardize patient health.

Healthcare Policies and Regulatory Landscape

The Ministry of Health and Population (MoHP) oversees Egypt's healthcare policy and regulatory framework, which are principally governed by the Egyptian Medical Facilities Law, the Egyptian Drug Authority (EDA), and the Egyptian Diagnostics Clinical Laboratories Law. Egypt's healthcare system has continually integrated the public and private sectors, with ongoing programs aimed at improving medical facilities, increasing service availability, and expanding healthcare access to underprivileged areas. To diversify service options, the country has developed health policies and interacts with the private sector.

Significant modifications are taking place in the Egyptian Health System, driving stakeholders to acquire an improved understanding of the current framework and forecast future developments. The recent passage of the Social Health Insurance Law is a driving force in the effort to lower out-of-pocket payments.

Competitive Landscape

Key Players

Sun Pharmaceuticals
Merck & Co
Cipla Limited
Johnson & Johnson
Lexington International LLC
Cirrus Hair Centers
Vita-Cos-Med-Klett-Loch
Capillus
Follica Inc
Transitions Hair Pty Ltd

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Egypt Alopecia Therapeutics Market Segmentation

By Disease Type

Alopecia Areata
Cicatricial Alopecia
Traction Alopecia
Alopecia Totalis
Androgenetic Alopecia
Alopecia Universalis
Others

By Treatment Type

Pharmaceuticals
Devices
Others

By Gender

Male
Female

By Route of Administration

Topical
Injectable
Oral

By Age Group

Below 18 years
18-34 years
35-49 years
50 years and above

By End User

Hospitals
Physician’s Office
Dermatology clinics
Others

By Sales Channel

Prescriptions
OTC

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.